Monoamine oxidase: Radiotracer chemistry and human studies

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 58, Issue 3, 2015, Pages 51-64

  Fowler, Joanna S ^a   Logan, Jean ^b   Shumay, Elena ^c   Alia Klein, Nelly ^d   Wang, Gene Jack ^c   Volkow, Nora D ^c,e  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

human studies; monoamine oxidase; PET; radiotracer chemistry

Indexed keywords

AMINES; BIOCHEMISTRY; DRUG DOSAGE; NEUROPHYSIOLOGY; RADIOACTIVE TRACERS;

DOPAMINE; EXOGENOUS SOURCE; HEALTHY VOLUNTEERS; HUMAN BIOLOGY; HUMAN STUDY; INHIBITOR DRUGS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON'S DISEASE; RADIOTRACER CHEMISTRY;

POSITRON EMISSION TOMOGRAPHY;

AMINE OXIDASE (FLAVIN CONTAINING); SELEGILINE; TRACER;

ALCOHOLISM; ARTICLE; COMPARTMENT MODEL; DEPRESSION; DRUG RESEARCH; ENZYME BLOOD LEVEL; GENOTYPE; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN CONTENT; PROTEIN EXPRESSION; RADIOCHEMISTRY; VOLUME OF DISTRIBUTION; BRAIN; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; GENETICS; METABOLISM; PROCEDURES;

BRAIN; DRUG DISCOVERY; GENOTYPE; HUMANS; MONOAMINE OXIDASE; RADIOACTIVE TRACERS; RADIOCHEMISTRY;

EID: 84925457857     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.3247     Document Type: Article

References (114)

1. J. P. M. Finberg, Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulations of CNS monoamine neurotransmitter release. Pharmacol. Ther. 2014. 10.1016/j.pharmthera.2014.02.010.
2. D. E. Edmondson, Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr. Pharm. Des. 2014, 20, 155-160.
3. B. Bellau, J. Moran, Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase. Ann. N. Y. Acad. Sci. 1963, 107, 822-839.
4. J. Saura, E. Nadal, B. van den Berg, M. Vila, J. A. Bombi, N. Mahy, Localization of monoamine oxidases in human peripheral tissues. Life Sci. 1996, 59, 1341-1349.
5. J. C. Shih, R. F. Thompson, Monoamine oxidase in neuropsychiatry and behavior. Am. J. Hum. Genet. 1999, 65, 593-598.
6. K. I. Shulman, N. Herrmann, S. E. Walker, Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 2013, 27, 789-797.
7. E. A. Zeller, J. Barsky, E. R. Berman, Amine oxidases. XI. Inhibition of monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. J. Biol. Chem. 1955, 214, 267-274.
8. J. P. Finberg, K. Gillman, Selective inhibitors of monoamine oxidase type B and the 'cheese effect'. Int. Rev. Neurobiol. 2011, 100, 169-190.
9. K. R. Krishnan, Revisiting monoamine oxidase inhibitors. J. Clin. Psychiatry 2007, 68 (Suppl 8), 35-41.
10. J. S. Fowler, J. Logan, J. N. D. Volkow, G.-J. Wang, R. R. MacGregor, Y. S. Ding, Monoamine oxidase: radiotracer development and human studies. Methods 2002, 27, 263-277.
11. J. S. Fowler, J. Logan, N. D. Volkow, G.-J. Wang, Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol. Imaging Biol. 2005, 7, 377-387. Review
12. K. I. Kersemans, N. Van Laeken, F. De Vos, Radiochemistry devoted to the production of monoamine oxidase (MAO-A and MAO-B) ligands for brain imaging with positron emission tomography. J. Labelled Comp. Radiopharm. 2013, 56, 78-88.
13. J. P. Holland, P. Cumming, N. Vasev, PET radiopharmaceuticals for probing enzymes in the brain. Am. J. Nucl. Med. Mol. Imaging. 2013, 3, 194-216.
14. 11C]octylamine as a substrate. Biochem. Pharmacol. 1977, 26, 1917-1922.
15. 11C-Labeled octylamine, a potential diagnostic agent for lung structure and function. J. Nucl. Med. 1976, 17, 752-754.
16. J. S. Fowler, B. M. Gallagher, R. R. MacGregor, A. P. Wolf, Carbon-11 labeled aliphatic amines in lung uptake and metabolism studies: potential for dynamic measurements in vivo. J. Pharmacol. Exp. Ther. 1976, 198, 133-145.
17. R. R. MacGregor, J. S. Fowler, A. P. Wolf, C. Halldin, B. Langstrom, Synthesis of suicide inhibitors of monoamine oxidase: carbon-11 labeled clorgyline, l -deprenyl and d -deprenyl. J. Labeled Compounds and Radiopharm. 1987, 25, 1-8.
18. 11C]clorgyline binding in brain. Nucl. Med. Biol. 2001, 28, 779-785.
19. D. E. Edmondson, L. DeColibus, C. Binda, M. Li, A. Mattevi, New insights into the structures and functions of human monoamine oxidases A and B. J. Neural Transm. 2007, 114 (6), 703-5. Epub 2007 Mar 29.
20. 11C]-L-deprenyl in mice: potential for measurement of functional monoamine oxidase activity in brain using positron emission tomography. Biochem. Pharmacol. 1985, 34, 3207-3210.
21. 11C] l -deprenyl in living baboon brain. J. Neurochem. 1988, 51, 1524-1534.
22. 11C-labeled MAO A inhibitors and their in vivo uptake kinetics. Nucl. Med. Biol. 1997b, 24, 381-388
23. 11C-suicide inactivators and positron emission tomography. Science 1987, 235, 481-485.
24. 11C] l -deprenyl-D2 for MAO B mapping. J. Nucl. Med. 1995, 36, 1255-1262.
25. J. S. Fowler, J. Logan, Y.-S. Ding, D. Franceschi, G.-J. Wang, N. D. Volkow, N. Pappas, D. Schlyer, D. Schlyer, S. J. Gatley, D. Alexoff, C. Felder, A. Biegon, W. Zhu, Non-MAO A binding of clorgyline in white matter in human brain. J. Neurochem. 2001, 79, 1039-1046.
26. 11C]clorgyline. J. Cereb. Blood Flow Metab. 2002, 22, 1367-1376.
27. J. S. Fowler, J. Logan, G.-J. Wang, D. Franceschi, N. D. Volkow, F. Telang, N. Pappas, R. Ferrieri, C. Shea, V. Garza, Y. Xu, P. King, D. Schlyer, S. J. Gatley, Y.-S. Ding, D. Warner, N. Netusil, P. Carter, M. Jayne, D. Alexoff, W. Zhu, P. Vaska, Monoamine oxidase A imaging in peripheral organs in healthy human subjects. Synapse 2003, 49, 178-187.
28. J. S. Fowler, J. Logan, G.-J. Wang, N. D. Volkow, W. Zhu, D. Franceschi, N. Pappas, R. Ferrieri, C. Shea, V. Garza, Y. Zhu, R. R. MacGregor, D. Schlyer, S. J. Gatley, Y.-S. Ding, D. Alexoff, PET imaging of monoamine oxidase B in peripheral organs in humans. J. Nucl. Med. 2002, 43, 1331-1338.
29. J. S. Fowler, N. D. Volkow, J. Logan, D. Franceschi, G.-J. Wang, R. MacGregor, C. Shea, V. Garza, N. Pappas, P. Carter, N. Netusil, P. Bridge, D. Liederman, A. Elkashef, J. Rotrosen, R. Hitzemann, Evidence that l -deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 2001, 68, 2759-2768.
30. J. Logan, Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol. 2000, 27, 661-670.
31. J. Tong, J.-H. Meyer, Y. Furukawa, I. Boileau, L. J. Chang, A. A. Wilson, S. Houle, S. J. Kish, Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2013, 33, 863-871.
32. O. Inoue, T. Tominaga, T. Yamasaki, H. Kinemuchi, Radioactive N. N-dimethylphenylethylamine: a selective radiotracer for in vivo measurement of monoamine oxidase-B activity in the brain. J. Neurochem. 1985, 44, 210-216.
33. 11C-Labelling of dimethylphenethylamine in two different positions and biodistribution studies. Int. J. Rad. Appl. Instrum. A 1989, 40, 557-560.
34. 11C]N,N-dimethylphenylethylamine in mice and humans: potential for measurement of brain MAO-B activity. J. Nucl. Med. 1987, 28, 1006-1111.
35. 11C-Harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl. Med. Biol. 1997, 24, 287-293.
36. M. Bergström, G. Westerberg, G. Németh, M. Traut, G. Gross, G. Greger, H. Müller-Peltzer, A. Safer, S. A. Eckernäs, A. Grahnér, B. Långström, MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur. J. Clin. Pharmacol. 1997, 52, 121-128.
37. 11C]-harmine binding to monoamine oxidase-A in the human brain. J. Cereb. Blood Flow Metab. 2006, 26, 330-344.
38. 11)C]-harmine positron emission tomography study. J. Cereb. Blood Flow Metab. 2012, 32, 443-446.
39. 11C]befloxatone, a selective radioligand for the in vivo imaging of MAO-A density using PET. J Labeled Cmpnds. Radiopharm. 2003, 46, 783-792.
40. 11C]befloxatone. J. Pharmacol. Exp. Ther. 2003, 305, 467-473.
41. 11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A. Eur J. Nucl. Med. Molec. Imaging Res. 2013, 3, 78.
42. R. di Santo, R. Costi, A. Roux, M. Artico, O. Befani, T. Meninno, E. Agostinelli, P. Palmegiani, P. Turini, R. Cirilli, R. Ferretti, B. Gallinella, F. la Torre, Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. J. Med. Chem. 2005, 48, 4220-4223.
43. 11)C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone, a novel tracer for positron emission tomography studies of monoamine oxidase type A. J. Med. Chem. 2008, 51, 1617-1622.
44. 11C]SL25.1188), a novel radioligand for imaging monoamine oxidase-B with PET. J. Label. Compd. Radiopharm. 2008, 51, 153-158
45. 11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse 2010, 64, 61-69.
46. 11C]CO2 fixation for imaging monoamine oxidase B. J. Label. Cmpnd. Radiopharm. 2011, 54, 678-680.
47. 11C]SL25.1188 in human brain with high-resolution positron emission tomography. J. Cereb. Blood Flow Metab. 2014, 34, 883-889.
48. 11C]befloxatone distribution is well correlated to monoamine oxidase A protein levels in the human brain. J. Cereb. Blood Flow Metab. 2014, 34, 1951-1952.
49. 11C -methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain. J. Med. Chem. 1990, 33, 2015-2019.
50. 18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction. Int. J. Rad. Appl. Instrum. A 1991, 42, 121-127.
51. 18F-Fluorohexyl)-N-methylpropargylamine: a fluorine-18-labeled monoamine oxidase B inhibitor for potential use in PET studies. Nucl. Med. Biol. 1999, 26, 111-116.
52. N. Vasdev, O. Sadovski, M. D. Moran, J. Parkes, J. J. Meyer, S. Houle, A. A. Wilson, Development of new radiopharmaceuticals for imaging monoamine oxidase B. Nucl. Med. Biol. 2011, 38, 933-943.
53. S. Nag, L. Lehmann, T. Heinrich, A. Thiele, G. Kettschau, R. Nakao, B. Gulyás, C. Halldin, Synthesis of three novel fluorine-18 labeled analogues of l -deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). J. Med. Chem. 2011 54, 7023-7029.
54. 18F]fluorodeprenyl: a new MAO-B pet radioligand. Synapse 2012, 66, 323-330.
55. 18F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). Bioorg. Med. Chem. 2012, 20, 3065-3071.
56. S. Nag, L. Lehmann, G. Kettschau, M. Toth, T. Heinrich, A. Thiele, A. Varrone, C. Halldin, Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). Bioorg. Med. Chem. 2013, 21, 6634-6641.
57. S. Nag, G. Kettschau, T. Heinrich, A. Varrone, L. Lehmann, B. Gulyas, A. Thiele, E. Keller, C. Halldin, Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. Bioorg. Med. Chem. 2013, 21, 186-195.
58. 18F-fluoroclorgyline) as a potential PET radiotracer for monoamine oxidase-A. Nuc.l. Med. Biol. 1999, 26, 619-625.
59. M. Hirata, Y. Magata, H. Saji, A. Yokoyama, Radiofluorinated clorgyline derivative for mapping MAO-A activity in brain with PET. J. Labeled. Cmpnd. Radiopharm. 1994, 35, 234-235.
60. Y. Ohmomo, M. Hirata, K. Murakami, Y. Magata, C. Tanaka, A. Yokoyama, Synthesis of fluorine and iodine analogues of clorgyline and selective inhibition of monoamine oxidase A. Chem. Pharm. Bull. (Tokyo), 1991, 39, 1038-1040.
61. H. G. Brunner, M. Nelen, X. O. Breakefield, H. H. Ropers, B. A. van Oost, Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993, 262, 578-580.
62. J. W. Lenders, G. Eisenhofer, N. G. Abeling, W. Berger, D. L. Murphy, C. H. Konings, L. M. Wagemakers, I. J. Kopin, F. Karoum, A. H. van Gennip, H. G. Brunner, Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J. Clin. Invest. 1996, 97, 1010-1019.
63. J. C. Shih, K. Chen, MAO-A and -B gene knock-out mice exhibit distinctly different behavior. Neurobiology (Bp.) 1999, 7, 235-246.
64. S. Z. Sabol, S. Hu, D. Hamer, A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 1998, 103, 273-279.
65. A. Caspi, J. McClay, T. E. Moffitt, J. Mill, J. Martin, I. W. Craig, A. Taylor, R. Poulton, Role of genotype in the cycle of violence in maltreated children. Science 2002, 297, 851-854.
66. H. M. Dorfman, A. Meyer-Lindenberg, J. W. Buckholtz, Neurobiological mechanisms for impulsive-aggression: the role of MAOA. Curr. Top. Behav. Neurosci. 2014, 17, 297-313.
67. J. S. Fowler, N. Alia-Klein, A. Kriplani, J. Logan, B. Williams, W. Zhu, I. W. Craig, F. Telang, R. Goldstein, N. D. Volkow, P. Vaska, G.-J. Wang, Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol. Psychiatry 2007, 62, 355-358.
68. E. Shumay, J. Logan, N. D. Volkow, J. S. Fowler, Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men. Epigenetics. 2012, 7, 1151-1160.
69. Y. Liu, X. Li, M. J. Aryee, T. J. Ekström, L. Padyukov, L. Klareskog, A. Vandiver, A. Z. Moore, T. Tanaka, L. Ferrucci, M. D. Fallin, A. P. Feinberg, GeMes, clusters of DNA methylation under genetic control, can inform genetic and epigenetic analysis of disease. Am. J. Hum. Genet. 2014, 94, 485-495.
70. N. Alia-Klein, R. Z. Goldstein, A. Kriplani, J. Logan, D. Tomasi, B. Williams, F. Telang, E. Shumay, A. Biegon, I. W. Craig, F. Henn, G.-J. Wang, N. D. Volkow, J. S. Fowler, Brain monoamine oxidase A activity predicts trait aggression. J. Neurosci. 2008, 28, 5099-5104.
71. A. Soliman, R. M. Bagby, A. A. Wilson, L. Miler, M. Clark, P. Rusjan, J. Sacher, S. Houle, J. H. Meyer, Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. Psychol. Med. 2011, 41, 1051-1060.
72. J. S. Fowler, J. Logan, G.-J. Wang, N. D. Volkow, Monoamine oxidase and cigarette smoking. NeuroToxicology 2003, 24, 75-82.
73. J. S. Fowler, N. D. Volkow, G. J. Wang, N. Pappas, J. Logan, C. Shea, D. Alexoff, R. R. MacGregor, D. J. Schlyer, I. Zezulkova, A. P. Wolf, Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 14065-14069.
74. J. S. Fowler, N. D. Volkow, G. J. Wang, N. Pappas, J. Logan, R. MacGregor, D. Alexoff, C. Shea, D. Schlyer, A. P. Wolf, D. Warner, I. Zezulkova, R. Cilento, Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379, 733-736.
75. J. S. Fowler, N. D. Volkow, J. Logan, N. Pappas, P. King, R. MacGregor, C. Shea, V. Garza, S. J. Gatley, An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci. 1998, 63, PL 19-23.
76. J. S. Fowler, G.-J. Wang, N. D. Volkow, D. Franceschi, J. Logan, N. Pappas, C. Shea, R. R. MacGregor, V. Garza, Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. Nicotine Tob. Res. 1999, 1, 325-329.
77. J. S. Fowler, G.-J. Wang, N. D. Volkow, D. Franceschi, J. Logan, C. Shea, R. R. MacGregor, V. Garza, Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. Am. J. Psychiatry 2000, 157, 1864-1866.
78. C. Leroy, V. Bragulat, I. Berlin, M. C. Grégoire, M. Bottlaender, D. Roumenov, F. Dollé, S. Bourgeois, J. Penttilä, E. Artiges, J. L. Martinot, C. Trichard, Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J. Clin. Psychopharmacol. 2009, 29, 86-88.
79. J. S. Fowler, J. Logan, G. J. Wang, N. D. Volkow, F. Telang, W. Zhu, D. Franceschi, C. Shea, V. Garza, Y. Xu, Y. S. Ding, D. Alexoff, D. Warner, N. Netusil, P. Carter, M. Jayne, P. King, Vaska P comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers. J. Nucl. Med. 2005, 46, 1414-1420.
80. J. S. Fowler, J. Logan, G.-J. Wang, N. D. Volkow, F. Telang, W. Zhu, D. Franceschi, N. Pappas, R. Ferrieri, C. Shea, V. Garza, Y. Xu, D. Schlyer, S. J. Gatley, Y.-S. Ding, D. Alexoff, D. Warner, N. Netusil, P. Carter, M. Jayne, P. King, P. Vaska, Low monoamine oxidase B in peripheral organs in smokers. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 11600-11605.
81. I. Bacher, S. Houle, X. Xu, L. Zawertailo, A. Soliman, A. A. Wilson, P. Selby, T. P. George, J. Sacher, L. Miler, S. J. Kish, P. Rusjan, J. H. Meyer, Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch. Gen. Psychiatry 2011, 68, 817-826.
82. J. H. Meyer, N. Ginovart, A. Boovariwala, S. Sagrati, D. Hussey, A. Garcia, T. Young, N. Praschak-Rieder, A. A. Wilson, S. Houle, Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006. 63, 1209-1216.
83. B. A. Matthews, S. J Kish, X. Xu, I. Boileau, P. M. Rusjan, A. A. Wilson, D. DiGiacomo, S. Houle, J. H. Meyer, Greater monoamine oxidase A binding in alcohol dependence. Biol. Psychiatry 2014, 75, 756-764.
84. R. D. Terry, R. DeTeresa, L. A. Hansen, Neocortical cell counts in normal human adult aging. Ann. Neurol. 1987, 21, 530-539.
85. J. Ekblom, S. S. Jossan, L. Oreland, E. Walum, S. M. Aquilonius, Reactive gliosis and monoamine oxidase B. J. Neural Transm. Suppl. 1994, 41, 253-258.
86. J. S. Fowler, N. D. Volkow, G. J. Wang, J. Logan, N. Pappas, C. Shea, R. MacGregor, Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging 1997, 18, 431-425.
87. 11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 1995, 36 (7), 712-21.
88. 18F-FDG in focal epilepsy. Acta Neurol. Scand. 2001, 103, 360-366.
89. J. S. Fowler, N. D. Volkow, R. Cilento, G.-J. Wang, C. Felder, J. Logan, Comparison of brain glucose metabolism and monoamine oxidase B (MAO B) in traumatic brain injury. Clin. Positron Imaging. 1999, 2, 71-79.
90. S. S. Jossan, J. Ekblom, S. M. Aquilonius, L. Oreland, Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography. J. Neural Transm. Suppl. 1994, 41, 243-248.
91. 11C](l)-deprenyl-D2 PET. J. Neurol. Sci. 2007, 255, 17-22.
92. H. Engler, P. O. Lundberg, K. Ekbom, I. Nennesmo, A. Nilsson, M. Bergström, H. Tsukada, P. Hartvig, B. Långström, Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur. J. Nucl. Med. Mo.l Imaging. 2003, 30, 85-95.
93. 11C]- l -deprenyl using whole hemisphere autoradiography. Neurochem. Int. 2011, 58, 60-68.
94. 18F-FDG. J. Nucl. Med. 2012, 53, 37-46.
95. J. S. Fowler, N. D. Volkow, G. J. Wang, Y.-S. Ding, S. L. Dewey, PET and drug research and development. J. Nucl. Med. 40, 1154-63, 1999. Review.
96. R. Nutt, L. J. Vento, M. H. Ridinger, In vivo molecular imaging biomarkers: clinical pharmacology's new 'PET'? Clin. Pharmacol. Ther. 81, 792-5, 2007.
97. S. Chajkowski-Scarry, J. M. Rimoldi, Monoamine oxidase A and B substrates: probing the pathway for drug development. Future Med. Chem. 2014, 6, 697-717.
98. C. J. Bench, G. W. Price, A. A. Lammertsma, J. C. Cremer, S. K. Luthra, D. Turton, R. J. Dolan, R. Kettler, J. Dingemanse, M. da Prada, K. Biziere, G. R. McClelland, V. L. Jamieson, N. D. Wood, R. S. J. Frackowiak, Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose response study with the irreversible inhibitor Ro19 6327. Eur. J. Clin. Pharmacol. 10, 169-173, 1991.
99. J. S. Fowler, N. D. Volkow, J. Logan, D. J. Schlyer, R. R. MacGregor, G.-J. Wang, Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 43, 1984-92, 1993.
100. J. S. Fowler, N. D. Volkow, J. Logan, J, G.-J. Wang, R. R. MacGregor, D. Schlyer, et al,., Slow recovery of human brain MAO B after l -deprenyl (selegiline) withdrawal. Synapse 18, 86-93, 1994.
101. N. M. Freedman, E. Mishani, Y. Krausz, J. Weininger, H. Lester, E. Blaugrund, D. Ehrlich, R. Chisin, In vivo measurement of brain monoamine oxidase B occupancy by rasagiline using (11C)- l -deprenyl and PET. J. Nucl Med. 2005, 46, 1618-1624.
102. 11C]deprenyl. J. Neurochem. 1987, 49, 533-527.
103. 11C- l -deprenyl. J. Neural Transm. Suppl. 1990, 32, 55-59.
104. J. Saura, J. M. Luque, A. M. Cesura, M. da Prada, V. Chan-Palay, G. Huber, J. Löffler, J. G. Richards, Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994, 62, 15-30.
105. 11C]- l -deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin. Pharmacol. Ther. 2009, 85, 506-512.
106. 11C]-harmine PET study. J. Psychiatry Neurosci. 2011, 36, 375-382.
107. H. L. White, P. W. Scates, B. R. Cooper, Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci. 1996, 58, 1315-1321.
108. J. S. Fowler, J. Logan, A. J. Azzaro, R. M. Fielding, W. Zhu, A. K. Poshusta, D. Burch, B. Brand, J. Free, M. Asgharnejad, G.-J. Wang, F. Telang, B. Hubbard, M. Jayne, P. King, P. Carter, Y. Xu, C. Shea, L. Muench, D. Alexoff, E. Shumay, M. Schueller, D. Warner, K. Apelskog-Torres, Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010, 35, 623-631.
109. B. Smith, K. Uhl, Drug delivery in the twenty-first century: a new paradigm. Clin. Pharmacol. Ther. 2009, 85, 451-455.
110. J. S. Fowler, J. Logan, N. D. Volkow, E. Shuay, F. McCall-Perez, M. Gilmor, M. Jayne, Y Wang, D. L. Alexoff, K. Apelskog-Torres, B. Hubbard, P. Carter, P. King, S. Fahn, F. Telang, C. Shea, Y. Xu, L. Muench, Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 2014, Sep 24.
111. J. B. Wu, C. Shao, X. Li, Q. Li, P. Hu, C. Shi, Y. Li, Y. T. Chen, F Yin, C. P. Liao, B. L. Stiles, H. E. Zhau, J. C. Shih, L. W. Chung, Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J. Clin. Invest. 2014, 124, 2891-2908.
112. A, M, Gabilondo, C. Hostalot, J. M. Garibi, J. J. Meana, L. F. Callado, Monoamine oxidase B activity is increased in human gliomas. Neurochem. Int. 2008, 52, 230-234.
113. R. H. Abeles, A. L. K. Maycock, Suicide enzyme inactivators. Acc. Chem. Res. 1976, 9, 313-319.
114. J. S. Fowler, J. Logan, G.-J. Wang, N. D. Volkow, F. Telang, Y.-S. Ding, C. Shea, V. Garza, Y. Xu, Z. Li, D. Alexoff, P. Vaska, R. Ferrieri, D. Sch;lyer, W. Zhu, S. J. Gatley, Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C] l -deprenyl in brain and peripheral organs in humans. Nucl. Med. Biol. 2004, 31, 313-319.